This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility. (Pomegranate)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2013 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Hillel Yaffe Medical Center Identifier:
First received: July 14, 2013
Last updated: August 6, 2013
Last verified: July 2013

Some animal studies revealed that the pomegranate juice may improve sperm quality in terms of concentration, motility and morphology, as well as in fertilization rate.

Minor data is available regarding the influence on male sperm.

Condition Intervention Phase
Male Infertility With Severe Oligo-terato-asteno-spermia Dietary Supplement: Pomegranate pills Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.

Resource links provided by NLM:

Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • pregnancy [ Time Frame: 24 month ]

Secondary Outcome Measures:
  • ROS (reactive oxidative stress )and Interleukins level in semen fluid [ Time Frame: 12 weeks ]
    The unit for measure the ROS are Micromolar epicatechin equivalent

Estimated Enrollment: 55
Study Start Date: September 2013
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: No Pills
Patients in this group will not receive Pomegranate pills.
Active Comparator: Pomegranate pills
The reccruited patient will receive pomegranate pills every day for 12 weeks. The control group will not be exposed for the pills.
Dietary Supplement: Pomegranate pills

Detailed Description:
Pomegranate contains a high concentration of vitamins ( C, B1, B2, B3, B5), potassium, Magnesium , Zinc and is a good source for polyphenols .Polyphenols molecules have been found to possess antioxidant properties and may effects the expression of different genes . Recent studies indicate that among foods that contain polyphenols, juice extracted from the pomegranate has the highest concentration of measurable polyphenols . Pomegranates have shown inhibitory effect on NF-κB and the MAP kinases JNK and ERK, which are critical steps in the cascade of events leading to inflammatory response. The NF- κB pathway is activated in response to bacterial infection and initiates the inflammatory cascade, which may explain the protective effect of Pomegranates on bacterial infections.

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • TMC of less than 5 million spermatogonia in native sperm and morphology less than 4% by Kruger criteria.

Exclusion Criteria:

  • sensitivity to Pomegranate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01918163

Contact: Einat Shalom-Paz, MD 972544899155
Contact: Ellenbogen Adrian, MD 973506246722

Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: Reuma Barkan    97246304223   
Sponsors and Collaborators
Hillel Yaffe Medical Center
Principal Investigator: Einat Shalom-Paz, MD Hillel Yaffe Medical center, IVF unit, Hadera, Israel
  More Information

Responsible Party: Hillel Yaffe Medical Center Identifier: NCT01918163     History of Changes
Other Study ID Numbers: 0059-13HYMC
Study First Received: July 14, 2013
Last Updated: August 6, 2013

Keywords provided by Hillel Yaffe Medical Center:
pomegranate pills, male infertility, pregnancy rate, semen analysis, ROS, oxidative stress

Additional relevant MeSH terms:
Infertility, Male
Genital Diseases, Male
Genital Diseases, Female processed this record on September 21, 2017